Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

BackgroundTrifluridine/tipiracil (FTD/TPI) is approved as monotherapy and in combination with bevacizumab for the treatment of patients with refractory metastatic colorectal cancer (mCRC). FTD/TPI plus bevacizumab showed good tolerability in the phase 3 SOLSTICE (first-line) and SUNLIGHT (later-line...

Full description

Saved in:
Bibliographic Details
Main Authors: Julien Taieb, Marwan Fakih, Gabor Liposits, Gerald W. Prager, Eric Van Cutsem, Fortunato Ciardiello, Nadia Amellal, Elizabeth Calleja, Mei Liu, Lucas Roby, Josep Tabernero, Thierry André
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
clinical trial
first-line
SOLSTICE
SUNLIGHT
third-line
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1506075/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items